Development and validation of an alpha fetoprotein immunoassay using Gyros technology

Area of Science:

• Biochemistry and Molecular Biology
• Oncology
• Analytical Chemistry

Background:

• Alpha fetoprotein (AFP) is a key biomarker for hepatocellular carcinoma (HCC) diagnosis and prognosis.
• Current AFP assays require large sample volumes, limiting their use in small animal models.
• There is a need for sensitive, sample-sparing assays for AFP in pre-clinical oncology research.

Purpose of the Study:

• To develop and validate a novel, automated microimmunoassay for quantifying circulating AFP.
• To enable sensitive AFP detection in low-volume samples for pre-clinical drug development.
• To assess the utility of AFP as a pharmacodynamic endpoint in rodent cancer models.

Main Methods:

• Utilized the Gyrolab™ automated microimmunoassay platform for AFP detection.
• Screened commercially available antibodies and optimized reaction conditions using Design of Experiments (DOE).
• Performed analytical validation including accuracy, precision, dilutional linearity, and stability assessments.

Main Results:

• Developed a reliable AFP immunoassay with total error <30% across tested concentrations.
• Demonstrated measurable AFP levels in diseased mice and undetectable levels in normal mice.
• The assay requires minimal sample volume, suitable for serial sampling in rodent studies.

Conclusions:

• The novel, low-volume AFP immunoassay is analytically validated and suitable for pre-clinical research.
• This assay facilitates the use of AFP as a pharmacodynamic biomarker in rodent cancer models.
• The miniaturized format supports serial sampling, enhancing its utility in drug development.